Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019
An observational study
Bibliographic Data
| ID | 21467529 |
|---|---|
| Authors | Frank Moriarty (0000-0001-9838-3625, Royal College of Surgeons in Ireland, corresponding author), James Larkins (0000-0003-4339-5623), James Larkin (0000-0001-5569-9523), Tom Fahey (0000-0002-5896-5783) |
| Year | 2021 |
| Volume | 125 |
| Issue | 10 |
| Pages | 1297-1304 |
| Publication date | 2021-10-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Health Policy (JOURNAL) |
| Journal identifiers | ISSN: 0168-8510 • E-ISSN: 1872-6054 |
| Publisher | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.healthpol.2021.07.016 |
| PMID | 34429238 |
| OpenAlex | W3192973710 |
| Language | EN |
| Citations received | 4 |
| References cited | 34 |
BACKGROUND: The pharmaceutical industry makes large numbers of payments to healthcare organisations (HCOs) and healthcare professionals (HCPs). Ireland has a large pharmaceutical industry presence and national debate on legislating for greater industry payment transparency. This study characterises payments in Ireland to HCPs and HCOs during 2015-2019, and the content, consistency and methodology of the data source. METHODS: An observational study of TransfersOfValue.ie, the disclosure website for the Irish Pharmaceutical Health Association pharmaceutical companies. We conducted a quantitative analysis, summarising payments to HCOs, HCPs and for research and development (R&D). We quantified disclosure rates of names for HCP and HCO payment recipients. We also conducted a content analysis of the methodology notes and website content. RESULTS: Payments totalling €163 million were reported by 47 companies during 2015-2019, €84.6 million for R&D, with non-R&D payments of €45.1 million to HCOs and €33.6 million to HCPs. HCOs were named for 91.2% of payments, and HCPs for 55.1-62.8% across study years. For 2019, ten companies disclosed >€1 million in payments, and three disclosed >€1 million in HCO and HCP payments. Content analysis of 132 data reports and 46 methodology notes indicated substantial variation in methodologies for reporting between companies. CONCLUSIONS: There are substantial payments in Ireland, often the recipient is undisclosed, and companies differ in their reporting. A mandatory disclosure system could enhance transparency
Business · Conflict of interest · Economic growth · Economics · Health care · Irish · Observational study · Payment · Pharmaceutical industry · Political science · Law · Medicine · Pharmaceutical Economics and Policy · Pharmaceutical industry and healthcare · Pharmacovigilance and Adverse Drug Reactions · Accounting · Finance · Marketing · Pharmacology
| Citations per year | 1 |
|---|---|
| Citation span | 2022 - 2024 (3) |
| Highly cited | No |